CDKN2A and central nervous system neoplasm: There are clear limitations with existing models, the most prevalent limitation being that most of these models represent high-grade CNS tumors with combined BRAFV600E expression and CDKN2A deletion; progression models that recapitulate progression from low grade to high grade tumors are not available.